Skip to main content

Fresenius reports personal data breach; separate cyberattack changes refrigeration settings at French blood-service sites

Fresenius reports a personal data breach. A separate cyberattack on a refrigeration supplier changed settings at three French blood-service sites. This issue also covers Singapore's healthcare outage, University Hospitals' recovery, an OpenSSH flaw and FDA device notices.

Share

CISO Quick Read

  • Fresenius Medical Care is investigating a personal data breach after an unauthorized person accessed an employee account and copied files in August. The company says patient care and medical devices were not affected.
  • A cyberattack on a refrigeration supplier changed temperature and defrost settings at three French blood-service sites. The service reported no identified health impact or blood-product losses. Hospitals and blood banks need a plan for temperature alarms, product transfers and loss of monitoring.
  • A shared Domain Name System (DNS) service, which translates network names into addresses, failed and disrupted Singapore's public healthcare services for about nine and a half hours. University Hospitals restored MyChart patient-portal access on November 7 while work to restore all services continued.
  • The Cybersecurity and Infrastructure Security Agency (CISA) says flaws in SonicWall firewall software and WordPress website software have been exploited. NHS England says researchers found working attack code for a Zyxel network switch flaw, which requires local network access.
  • SANS reported attempts to exploit OpenSSH CVE-2026-123158 against its decoy systems beginning November 5. OpenSSH provides secure remote access. Some Linux systems using the musl system library are exposed under specific SSH and account settings. Apply the appropriate fix and ensure the SSH service restarts as directed.
  • FDA posted a recall record for IntelePACS imaging software and an early alert involving ButterflyBVM resuscitators. The ButterflyBVM actions differ by product and lot. Replacement resuscitators must be in place before the affected removal lots are taken out of service; other specified lots require a pre-use procedure before every use.

Fresenius investigates personal data breach after employee account access

Fresenius Medical Care says an unauthorized person accessed an employee account on August 18 and viewed and copied company files. The company detected the activity and secured the account on August 19. On August 28, it determined that identifiable personal information was affected.

The company's November 5 notice says the review is continuing. The files may have included names, addresses, dates of birth, Social Security and medical record numbers, insurance information, and treatment or other health information. Fresenius has not reported how many individuals were affected. It says medical devices, patient care, manufacturing and business continuity were not affected. Once the data review is complete, Fresenius plans to notify affected individuals for whom it has contact information. People who receive a letter will be offered credit monitoring and identity-theft services. Fresenius notice

A compromised account can expose sensitive files while care continues. Security and privacy leaders need to know which accounts can reach patient information, what they can download and whether retained logs support an investigation into what information was accessed or copied.

Cyberattack on supplier changes refrigeration settings at French blood-service sites

An attack on a refrigeration supplier affected cold-storage controls at three sites operated by France's national blood service. Temperature and defrost thresholds were raised. Monitoring and alarms alerted staff, who brought affected equipment under control or transferred products and samples to other facilities. The service reported no identified health impact or blood-product losses, according to The Record, which quoted the blood service. The Record

Separately, CISA, the FBI, HHS, USDA and the Department of Transportation warned on November 5 of malicious activity targeting industrial refrigeration and cold-chain monitoring globally. Their fact sheet describes possible changes to temperature controls and loss of visibility into current temperatures. FDA also encouraged organizations to assess cold-chain infrastructure and disaster plans. Joint U.S. fact sheet · FDA notice

Hospitals, laboratories and blood banks should identify connected equipment protecting temperature-sensitive products and establish which suppliers can change its settings. Remove direct internet access to refrigeration controls, secure necessary remote connections and set alerts for unsafe temperatures. The downtime plan should specify where products can be moved, who receives an overnight alarm and how staff will decide whether affected stock remains usable.

Singapore traces healthcare outage to shared network service failure

A missed security update to a shared domain name system service contributed to a nine-and-a-half-hour disruption across Singapore's three public healthcare clusters on October 13. In a November 3 parliamentary response, the health ministry said the required change was not completed before a scheduled global change. The ministry found that the disruption was not a cyberattack and that patient data were not accessed without authorization, compromised or lost.

Appointment booking, visitor registration, medication dispensing and billing were affected. Hospitals used downtime procedures and manual workflows. About 4,000 outpatient appointments were rescheduled, with some patients delayed by up to two hours. The ministry reported no adverse patient-safety incidents attributed to the disruption.

The health system had two data centers, but both depended on the same DNS service and security configuration. Switching between them would not have resolved the failure. The ministry said its technology agency will improve change tracking, diagnosis and recovery arrangements. Singapore Ministry of Health

A backup site cannot restore a service if both sites depend on the same failed component. Infrastructure leaders should map shared DNS, identity and network dependencies across primary and recovery environments, verify that vendor-managed security changes are completed, and include partial failures in downtime exercises.

University Hospitals in Cleveland restores MyChart patient portal access as recovery continues

University Hospitals in Cleveland detected unusual activity on its servers on October 22 and disconnected systems from the internet. Its November 2 update said hospitals, emergency departments and physician offices remained open while restoration continued. University Hospitals incident page

MyChart became accessible again on November 7, according to Cleveland 19, which quoted the health system. University Hospitals said some features might not work fully and new test results or other information could be delayed while data are reconciled. The organization said it was still working to restore all services. Cleveland 19

Recovery plans need to spell out who reconciles results and messages after downtime, how urgent information reaches patients and how calls will be handled while portal features return.

Medical devices

FDA posts recall for IntelePACS imaging software over security and image-deletion risks

FDA posted a Class II recall record on November 4 for certain versions of Intelerad's IntelePACS software. Intelerad initiated the correction on September 10 and notified customers on September 15. The record covers 560 software platforms.

A cybersecurity vulnerability could allow a malicious user to take over an administrator session, alter or delete images or study data, or lock out legitimate users. A separate software issue could unintentionally delete image data from an external archive integration. Intelerad told affected customers they could continue using the system while corrections were pending, following their standard cybersecurity and access-control practices until the update is implemented.

Imaging and clinical engineering staff should match installed versions to the FDA record and coordinate the corrective update with Intelerad. FDA recall record Z-0357-2027

FDA warns holes in ButterflyBVM resuscitators can reduce airflow

FDA issued an early alert on November 3 about certain ButterflyBVM bag-valve-mask resuscitators. A hole can develop in the bellows and reduce ventilation. Compact Medical reported no serious injuries or deaths associated with the issue as of November 2.

The action differs by product and lot. Lots 000109 through 000117 are to be removed after replacement resuscitators are in place. If a device's packaging and labeling are missing, assume it is included in the removal lots. Apply the pre-use procedure before every use to the specific model and lot combinations listed for correction within 000081–000108. Do not use a unit that fails the procedure. Label a failed unit “DO NOT USE,” set it aside with its original packaging and contact Compact Medical.

Keep backup resuscitators available. If a hole appears during use, switch immediately to a backup and follow the manufacturer's instructions. Do not destroy a device that failed during patient use or is associated with a patient injury. Label it “DO NOT USE,” quarantine it with its original packaging and contact Compact Medical for instructions. Match the product and lot to FDA's notice. FDA continues to review the issue. FDA early alert

Priority vulnerabilities (CVEs)

  • SonicWall SonicOS firewall software: CISA added CVE-2026-19868 to its Known Exploited Vulnerabilities (KEV) catalog on November 6. A person with valid credentials for an alternate authentication method may bypass SAML sign-in controls and the multifactor authentication (MFA) they enforce. Investigate suspicious access and match the firewall generation to SonicWall's update path. Gen 8 version 8.2.2-8015 remains affected. SonicWall has published release notes for the fixed 8.2.3-8015 build. Availability in MySonicWall remains unverified; confirm the correct update before installation. Before a Gen 8 upgrade, export an encrypted configuration backup. SonicWall’s upgrade guidance says a downgrade after applying 8.2.3 settings is unsupported, deletes all LDAP users and resets all MFA settings.
  • OpenSSH remote-access software CVE-2026-123158 (SSHole): SANS reported exploitation attempts beginning November 5. Assess reachable SSH remote-login services on Alpine and other Linux systems using the musl system library, including servers, vendor appliances and cloud workloads. Exposure depends on authentication and account settings. Apply the distribution or appliance vendor’s fix and make sure the SSH service, called sshd, restarts as directed. If patching an Alpine host is delayed, follow Alpine's safe-access steps before disabling password authentication and restarting sshd. Alpine advisory · SANS report
  • WordPress Core website software: CVE-2026-119977 entered KEV on November 3. The upgrade-process flaw can allow code execution during an upgrade. Apply 7.1.4 or a later supported fixed release and verify that it is running. Investigate the site for signs of compromise, including activity before the update.
  • Apple WebKit browser engine: CISA added CVE-2024-27834 on November 4. Apple addressed this pointer-authentication bypass in May 2024. Verify that managed devices have a supported release containing the WebKit fix.
  • Zyxel GS1900 network switches: NHS England reports that researchers found a working exploit for CVE-2026-107441 on attacker-controlled infrastructure before disclosure. Exploitation requires local network access. Apply the model-specific 2.90 Patch 3 firmware. Patch 2 remains vulnerable. The CVE was absent from the November 6 KEV catalog. NHS assessment.

Vulnerability tracker (CVE and KEV)

Open a record for scope and response details. Federal due dates below apply to covered U.S. federal civilian agencies, not automatically to healthcare organizations. CCD's tracker uses a 14-day display interval from first tracking, separate from remediation deadlines. Some historical first-tracking dates remain under review.

New KEV additions were verified against CISA's KEV catalog, version 2026.11.06 when checked. The six continuing entries retain the KEV dates reported in the November 2 issue.

SonicWall SonicOS firewall software, CVE-2026-19868: CISA says this SSL VPN flaw has been exploited. A user with valid credentials for another sign-in method may bypass SAML controls and associated multifactor authentication. Gen 8 version 8.2.2-8015 remains affected; use the generation-specific guidance.

SonicWall's notice covers physical and virtual Gen 7 and Gen 8 firewalls. It lists Gen 7 versions 7.3.3-7015 and earlier as affected, with 7.3.4-7013 and above fixed. Gen 8 versions 8.2.2-8015 and earlier are affected; the named fix is 8.2.3-8015. The 8.2.3-8015 release notes list the corresponding SSL VPN authentication fix, GEN8-18361, as resolved. The separate support notice still describes the build as scheduled for November 6. Availability in MySonicWall remains unverified; confirm the correct update before installation.

Before a Gen 8 upgrade, export an encrypted configuration backup. SonicWall says a downgrade after applying 8.2.3 settings is unsupported, deletes all LDAP users and resets all MFA settings. SonicWall upgrade guidance

CISA added the CVE November 6; the federal due date is November 20. The Canadian notice corroborates exploitation but gives a different Gen 8 version boundary. Use SonicWall's affected and fixed version table.

SonicWall version table · SonicWall CVE record · SonicOS 8.2.3-8015 release notes · Exploitation notice

WordPress Core website software, CVE-2026-119977: CISA says attackers have exploited a flaw that can let them run code during a WordPress upgrade. Update affected sites and investigate activity around prior upgrades.

The flaw can permit remote code execution during the upgrade window. WordPress released 7.1.4 on October 28; use that release or a later supported version containing the fix. Confirm the actual running version, including sites maintained by a hosting provider.

CISA added the CVE November 3, with a November 6 federal due date. Its federal required action references forensic triage. Preserve and examine relevant evidence of compromise alongside remediation.

WordPress release · Affected-version and KEV notice

Apple WebKit browser engine, CVE-2024-27834: CISA has newly listed the flaw as exploited. Confirm devices contain Apple's existing fix.

This flaw bypasses a protection called pointer authentication. An attacker must already be able to read and change memory at locations of their choosing. Apple's fixes include Safari 17.5, iOS/iPadOS 16.7.8 and 17.5, macOS Sonoma 14.5, tvOS 17.5 and watchOS 10.5, released in May 2024. Match each device and operating-system branch to Apple's security notes and install a supported release containing the correction.

CISA added it November 4; the federal due date is November 18. The vulnerability was disclosed and fixed in 2024.

Apple security note · Apple security note for additional platforms · NIST vulnerability record · CVE Program record

Ivanti Connect Secure remote-access software, CVE-2026-111357: CISA reports exploitation of a flaw that could let an authenticated local user gain higher privileges. Apply current vendor guidance and investigate the appliance.

This local privilege-escalation flaw is part of an exploited Connect Secure chain. Confirm the supported branch and per-CVE fix with Ivanti. The full vendor applicability matrix was not independently recovered. Investigate for signs of compromise even if the integrity scan is clean; preserve relevant evidence and follow the incident investigation guidance.

CISA addition: October 30. Federal due date: November 2, now past.

Canadian Centre advisory and Ivanti links

Ivanti Connect Secure remote-access software, CVE-2026-118527: CISA reports exploitation of a flaw that could let an authenticated attacker place files on the appliance. Patch and investigate possible earlier access.

Authenticated file placement can be combined with other vulnerabilities in the Connect Secure chain. Select the supported release with Ivanti and retain evidence before recovery where feasible. The full per-CVE vendor matrix remains unverified. The chain also includes CVE-2026-104935.

CISA addition: October 30. Federal due date: November 13.

Canadian Centre advisory and Ivanti links

Self-managed GitLab code-hosting software, CVE-2026-97229: CISA reports exploitation of a flaw that could let an attacker run code without signing in. Upgrade the installed branch and use GitLab's detection guidance.

Malicious CI/CD regular expressions can enable code execution. Affected CE and EE releases are 19.2 before 19.2.8, 19.3 before 19.3.5 and 19.4 before 19.4.2. Install the matching fixed branch release. GitLab.com and Dedicated were patched.

CISA addition: October 29. Federal due date: November 1, now past.

GitLab fixes and detection resources

Cisco ASA and FTD firewall software, CVE-2026-76418: CISA reports exploitation of a flaw that can restart an affected VPN appliance. Apply Cisco's release-specific fix.

A crafted unauthenticated request can reload an appliance when SSL remote-access login is reachable and the relevant tunnel group uses secondary authentication. The stated impact is denial of service. Cisco lists no workaround; disabling secondary authentication reduces authentication security and needs a deliberate risk decision.

CISA addition: October 29. Federal due date: November 1, now past.

Cisco affected configurations and fix table

Linux operating system (Fragnesia), CVE-2026-46300: CISA reports exploitation of a flaw that could let a local attacker gain higher privileges. Apply the distribution fix and verify the running kernel.

Exposure depends on the kernel build and affected ESP-in-TCP path. Install the distribution-specific correction and complete any required restart. Public disclosure dates to May 13.

CISA addition: October 28. Federal due date: October 31, now past.

Red Hat · Canonical

VMware ESX virtualization software, CVE-2026-41709: CISA reports exploitation of a flaw that can let an administrator bypass some logs. Update affected systems.

A malicious administrator can perform certain actions without expected logs. Broadcom lists fixes including ESXi-9.1.0.0-25370933, ESXi-9.0.2.0100-25595025 and ESXi80U3j-25429389; select the correct product and supported upgrade path.

CISA addition: October 28. Federal due date: November 11. The advisory was disclosed July 29 and updated August 19.

Broadcom advisory

Attempts reported to exploit OpenSSH remote-login flaw

OpenSSH remote-access software, CVE-2026-123158 (SSHole): SANS reports attack attempts. Assess whether your configuration is affected, apply the appropriate fix and restart the SSH service as directed.

The flaw can let an attacker bypass password authentication on some Linux systems using musl when PAM, a Linux authentication framework, is absent or disabled. Alpine identifies the following conditions together: an attacker can reach sshd; the Alpine server package runs without PAM or with PAM disabled; password authentication is enabled; a login-eligible account has a * password field; and another local account has a $5$ or $6$ password hash. Alpine advisory · OpenSSH 10.6p2 release notes

Alpine systems using its PAM-enabled package with UsePAM yes, or with password authentication disabled, are not affected under the advisory. Containers that do not run sshd are not affected. Default PermitRootLogin prohibit-password blocks direct root password login. PermitRootLogin yes removes that protection, and another vulnerable account may provide a path to root through tools such as doas.

Install the fixed OpenSSH package for the Alpine branch and restart sshd. The package upgrade alone does not restart the running daemon. Alpine lists fixed versions for current and older branches in its advisory. If the update must wait, confirm working key-based or other safe access and keep the current session open. Disable password authentication and validate the sshd configuration before restarting. After restart, confirm the effective PasswordAuthentication setting is disabled and verify a new login before closing the old session.

SANS reported attempts against its decoy systems beginning November 5. Its researcher expected some logins to have succeeded, but the November 8 report did not confirm that. SANS described the data as limited. CISA's catalog version 2026.11.06 did not list this CVE in the checked snapshot, so no KEV deadline was assigned there. SANS report · CISA KEV catalog

NHS reports working attack code for Zyxel network-switch flaw

Zyxel GS1900 network switches, CVE-2026-107441: Researchers found working attack code that requires local network access. Install the model-specific 2.90 Patch 3 update.

An unauthenticated LAN-based attacker can send a crafted HTTP request that may execute operating-system commands. Zyxel's November 3 advisory covers GS1900-8, -8HP, -10HP, -16, -24, -24E, -24EP, -24HPv2, -48 and -48HPv2 on 2.90 Patch 2 or earlier. Each has a model-specific 2.90 Patch 3 package. Do not apply a different model's firmware.

NHS England's November 5 alert says researchers found a working exploit on attacker-controlled infrastructure before public disclosure and assesses further exploitation as likely. The CVE was absent from the checked November 6 KEV catalog, so no KEV federal due date was assigned.

Zyxel exact model and firmware table · NHS exploitation assessment

Retired from this active view: PHP CVE-2026-109618 and CVE-2026-109619 reached their November 4 display date; PHP CVE-2026-115560 reached November 6; Arista CVE-2026-114625 and Nextcloud CVE-2026-110447 reached November 8; Brotli CVE-2026-111497 reached November 9. Adobe Commerce CVE-2026-48356 was tracked before this window and entered CISA’s known-exploited catalog October 27; its original display date was not recovered. Their records remain in the November 2 issue. Keep remediation tracking separate from the dates used to display this list.

FDA recall tracker

Match the exact product, lot or software version before acting. An early alert is not a confirmed Class I classification. This selection combines continuing records with the current public alert list and a targeted database review; it is not a complete search of every newly posted FDA recall. CCD’s existing watch dates for the Medline and AVID kits are November 10 and November 11, respectively. Watch dates for HemosIL, Medline beds, B. Braun and Illumina remain under review, and newly posted additions have not yet been assigned CCD watch dates.

ButterflyBVM resuscitators: Bellows holes can reduce ventilation. Put replacement resuscitators in place before removing affected lots; specified earlier lots need a pre-use procedure before every use.

Bellows holes can reduce ventilation. The FDA alert was posted November 3; customer notices date to September 26 and October 7.

  • Removal: READY R300/R308 lots 000109, 000110, 000111, 000112, 000113, 000115, 000116 and 000117; ButterflyBVM A100/A108 lot 000114. Install replacement BVMs in each care location first, then stop use and quarantine. Treat a device without packaging and labeling as included in the removal lots. Do not destroy a unit that failed during patient use or is associated with a patient injury. Label it “DO NOT USE,” quarantine it with its original packaging and contact Compact Medical for instructions.
  • Correction: READY R300/R308 lots 000081, 000083, 000084, 000086, 000093, 000094, 000097, 000098, 000099, 000100, 000101, 000104, 000107 and 000108; A100/A108 lots 000090, 000091, 000096 and 000105; PLUS P200/P208 lots 000089, 000092, 000095 and 000106. Perform the pre-use procedure in the instructions for use before every use. Do not use a unit that fails. Label a failed unit “DO NOT USE,” set it aside with its original packaging and contact Compact Medical. Keep backup BVMs available. If a hole is found during use, switch immediately to a backup and follow the manufacturer’s instructions.

FDA exact lot/UDI table and complete instructions.

Intelerad IntelePACS imaging software: A newly posted Class II correction addresses a flaw that could let a malicious user take over an administrator session and a separate issue that could delete images. Maintain access controls pending the vendor correction.

Event 99971, Z-0357-2027, remains open and classified. FDA posted it November 4; Intelerad initiated the correction September 10 and notified customers September 15. One flaw could allow a malicious user to take over an administrator session, change or delete image/study data, or lock out legitimate users. A separate issue may unintentionally delete images from an external archive integration.

Only these IntelePACS builds are listed: PACS-4-3-4-R20; PACS-4-9-1-R80; PACS-4-12-1-R81 through R90; PACS-4-14-1-R46 through R137; PACS-4-16-1-R50 through R137; PACS-4-17-1-R23 through R117; PACS-4-18-1-R31 through R91; PACS-5-1-1-R17 through R102; PACS-5-2-1-R36 through R93; PACS-5-3-1-R26 through R128; PACS-5-4-1-R15 through R101; PACS-5-5-1-R7 through R89; PACS-5-6-1-R12 through R81; PACS-5-7-1-R2 through R61; PACS-5-8-1-R2 through R42; PACS-5-9-1-R8 through R19.

Intelerad permits continued use under standard cybersecurity and access controls until its correction is implemented. Notify potential users, retain the notice and return the acknowledgment. FDA's record lists no fixed build and contains no reports of exploitation or patient injury.

FDA scope and correction instructions

Medline ChloraPrep convenience kits: Class I removal for potential fungal contamination. Quarantine listed kit/lot combinations, complete the response form and destroy each whole affected kit.

The action applies only to the kits in FDA's affected-product list, containing ChloraPrep Clear 1 mL item 930480, lot 4032183, or FREPP Clear 1.5 mL item 930299, lot 4073005. Potential fungal contamination requires whole-kit disposal, including kits with older labels instructing removal of just the component. Unrelated kits are outside this notice.

Medline's customer letter dates to August 11; FDA's Class I communication is October 13.

FDA notice · Exact affected kit/lot list

AVID IV Start Kit: Class I removal for potential fungal contamination. Quarantine and destroy the whole KRIV26-02 kit, lot 1658437, after completing the response form.

The affected UDI is 10809160460481. The kit contains a ChloraPrep applicator with potential fungal contamination. This action does not extend to unrelated AVID kits. The customer letter is dated August 20; FDA's Class I communication is October 14.

FDA exact scope and instructions

HemosIL AcuStar HIT-IgG(PF4-H) test: Class I removal for false-negative risk. Destroy affected lots and arrange alternative antibody testing for heparin-induced thrombocytopenia.

Part 0009800127, lots B40005 and B38062, and part 0009802028, lots B40006 and B38063, are affected. Destroy remaining affected product and document it on the response form. The laboratory or treating clinician should decide whether prior results need review, follow-up or repeat testing using local procedures and clinical judgment, including for the two lots that expired November 1.

FDA posted the notice October 30.

FDA notice

Medline beds and accessories: Early alert for fire risk and the risk of patients becoming trapped. Follow interim precautions pending authorized repair or replacement.

The notice covers all Medline-brand beds and associated components. Updated October 24 instructions permit continued use with precautions. Unplug the bed except during repositioning. Do not use extension cords to power the bed. Have a second person assist when possible. Do not attempt independent repairs or modifications. Patients may still become trapped when the bed is unplugged; arrange the applicable remedy with Medline.

The customer notice is dated October 14; FDA listed the alert October 29.

FDA complete precautions

B. Braun Streamline Bloodline Set for Dialog+: An early alert warns that a leak or detachment can interrupt dialysis and cause blood loss or air entry. Stop use, quarantine and return the three affected lots.

Model SL-2010M2096, lots A2600099, A2600128 and A2600136, may have inadequate connector bonding. A leak or detachment can interrupt dialysis and cause blood loss or air entry. Notify users and follow the return instructions.

The customer letter is dated October 20; FDA's current index lists November 2.

FDA exact scope and return instructions

Illumina instruments and servers: Five Class II records address a 2024 network weakness that could compromise transmitted data. Confirm product-specific secure network settings and complete the verification form.

Event 99957 covers all lots of these products:

Illumina initiated the correction May 8, 2024; FDA posted the records October 30, 2026. The records describe a network weakness that could compromise transmitted data. The FDA records do not describe an attack. Follow each product's secure-protocol guidance and complete its verification form. All five records remain open and classified.

FDA posted the records below November 2–8; many manufacturers had initiated their actions earlier.

Philips Allura Xper imaging systems: Class II correction for a display that can freeze during a procedure. Stop image-guided manipulation and follow the restart instructions if the screen blanks or freezes.

FDA posted the record November 6; Philips initiated the correction October 1. The affected systems are the listed models and serial numbers running software R8.1.x or R8.2.x with a FlexVision monitor. The application can become unresponsive during clinical use.

If the monitor blanks or freezes during a procedure, suspend image-guided device manipulation and perform the cold restart in the instructions for use. Philips permits continued intended use subject to those instructions. The company plans to begin implementing a software correction by July 2028.

FDA model and serial-number list and instructions

Medtronic CareLink SmartSync: Class II correction for Bluetooth disconnections that can interrupt programming of implanted cardiac devices. Follow Medtronic's specific iPadOS guidance.

FDA posted three records November 6 after Medtronic initiated the correction September 24. They cover the SmartSync Device Manager app M01A02, programmer 24970A and RF head 24967. A Bluetooth disconnection during a patient session can result in undesirable or incomplete parameter programming. Match the installation to the manufacturer notice.

Tablets below iPadOS 26.6 should update to 26.6 or 26.6.1 only if either is available. If neither is available, Medtronic does not recommend an update at this time. Tablets already on 26.6 or 26.6.1 need no further action under this notice. Medtronic advises against updating to iPadOS 27 or later before it establishes compatibility, warning that doing so will leave SmartSync unusable until then.

FDA app record · FDA related records · Australian TGA notice and version guidance

Siemens ACUSON ultrasound systems: Class II correction for unintended Color Doppler activation that can make a system unresponsive. Do not change the cardiac preset configuration without Siemens assistance.

FDA posted four records November 6 for ACUSON Origin REF 11668590, Origin ICE REF 11669400, Sequoia REF 11148775 and Sequoia Select REF 11658635. All four records specify software 4.0 (VD10A). Siemens initiated the correction September 11 and issued its customer letter October 2.

The unintended setting can cause a crash or loss of response. Do not modify Image Preset Editor Cardiac settings without Siemens Healthineers Clinical Applications assistance. Contact Siemens if Color DTI is suspected to be enabled. Siemens recommends examining prior results only when a clinical assessment was made with Color DTI displayed.

Origin record · Origin ICE record · Sequoia record · Sequoia Select record · All four FDA records

Vesco Q enteral feeding pump: Class II recall because it may deliver more or less than prescribed. Patients sensitive to feed rate should stop using the pump and seek an alternative.

FDA posted the records November 6; Vesco initiated the recall October 8. The pump record covers VED-701 with software 6.0–7.8, covering units manufactured through November 5, 2025. Related records list six feed-set models; match each model and lot to its FDA record. The pump may deliver more or less than prescribed outside its labeled ±5% accuracy.

Patients sensitive to feed rate should stop using the Q pump and seek an alternative from their supplier. This includes some pediatric patients, patients whose insulin is dosed to the feed rate, patients with metabolic disorders requiring continuous carbohydrate delivery, patients with fluid restrictions or jejunal feeding, and anyone whose physician determines precise delivery is clinically necessary. Other patients may continue only under the supplemental instructions and treating clinician's assessment. The FDA record truncates the supplemental text, so obtain the complete instructions from Vesco and the treating clinician.

FDA pump record · FDA VED-050 feed-set record · Related feed-set records

LIAISON PLEX Gram-Negative Blood Culture Assay: Class II labeling correction. Repeat testing is recommended when a result is positive for a bacterial family but identifies no genus or species.

FDA posted the record November 5; Luminex initiated the correction October 5. Catalog 20-005-303 is affected across all lots. The previous instructions did not adequately explain these results, which can contribute to incorrect interpretation or delayed bloodstream-infection diagnosis.

If a result is positive for a bacterial family but identifies no genus or species, repeat testing with the LIAISON PLEX Gram-Negative Blood Culture Assay is recommended. Make the guidance available to microbiology staff and clinicians interpreting results.

FDA record and interpretation guidance

Remel YeastOne Broth: Class II recall because the test may incorrectly indicate that yeast is susceptible to antifungal drugs. Stop clinical use and assess prior results.

FDA posted the record November 3; Remel initiated the action October 19. Product YY3462, lot 440400, UDI-DI 848838018817 may produce falsely susceptible results, particularly for azole antifungals.

Do not use the affected lot for clinical testing. Destroy remaining inventory, examine previously reported susceptibility results, assess whether retesting is appropriate and return the acknowledgment form.

FDA lot and action instructions

Cardinal Presource kits with BD Alaris infusion sets: Class I records posted for specified kits. Quarantine affected kits and label them to direct removal of the recalled component.

FDA posted the Class I records November 2; Cardinal initiated the action September 24. Event 100058 covers specified kit and lot combinations containing BD Alaris Pump Infusion Sets used with the model 8100 pump module. Match the kit and lot to the applicable FDA record and Cardinal notice.

The detailed record directs customers to quarantine matching kits, alert clinicians and affix a visible warning label instructing removal and disposal of the recalled infusion-set component. Return the acknowledgment after labeling. This is a component-removal action, separate from Cardinal's September 23 use-instruction notice.

FDA representative kit/lot record and actions · Related FDA kit records

Edwards Commander M heart-valve delivery system: FDA posted a Class I record for the previously covered balloon-rupture issue. Quarantine, do not use and return the four affected lots.

The November 2 FDA posting is a classification update to the issue covered in CCD's October 19 edition. Edwards initiated the action October 5. Model 9880CM29A, lots 67718561, 67804014, 67887043 and 67887044, may have a manufacturing defect that can cause the balloon to rupture during use.

Quarantine affected units, do not use them and arrange return with Edwards. Complete and return the acknowledgment. Edwards asks customers to complete the acknowledgment and return steps within 15 days of receiving its notice. Other lot numbers are not covered by this record.

FDA Class I record · Earlier CCD coverage

Siemens Atellica CH and CI laboratory analyzers: Class II corrections for reagent carryover, when material from one test affects a later test. The issue can falsely raise HbA1c or lower direct bilirubin results. Follow the interim instructions until the specified analyzer software and test-definition update are installed.

FDA posted two records November 6. Siemens initiated the correction September 22 and sent its letter September 29. The affected reagents are HDLC, SMN 11537213, and TP_2, SMNs 11645755 and 11537228, across all lots. Reagent carryover, when material from one test affects a later test, can falsely elevate A1c_E or A1c_H and falsely lower DBil_2 results, including patient, quality-control or calibrator results.

The applicable analyzer software must be installed first: CH version 1.31.1 or CI version 1.31.51. Install the applicable CH Test Definitions package 1.2.1 when it becomes available on the system. Until both the applicable software and package are installed, follow Appendix B or C of the Siemens letter for the current software version. The FDA database omits these appendices, so obtain the letter for the complete interim instructions. If both are already installed, the notice says no further system action is required. Siemens’ September 29 letter requested return of the field-correction response form within 30 days.

FDA HDLC record · FDA TP_2 record

Cardinal Presource kits with BD Alaris sets: Separate Class I records warn of possible inaccurate infusions and delayed alarms. Match the kit and component to the notice before selecting the action.

FDA posted Class I records for event 100064 on November 7. This is separate from event 100058. The affected Presource kits contain BD Alaris pump infusion sets used with the model 8100 pump module.

Match the kit catalog and work-order identifiers and component to FDA's Presource workbook, then confirm the component’s performance-affected or discontinued category with the manufacturer. If the identified set's performance is not clinically appropriate, use an alternative pump. If no syringe pump is available and the exact set is confirmed to fall under the performance-disclosure guidance, FDA describes cautious use with enhanced clinical monitoring and prior warnings. FDA separately directs that sets listed as discontinued in the BD workbook be discarded; they are not eligible for that conditional-use pathway. Follow the full FDA notice and manufacturer instructions for the applicable set.

FDA Presource kit workbook · BD set-category workbook · FDA Presource notice · FDA BD Alaris instructions · FDA record Z-0329 · FDA record Z-0330

Medtronic ear tubes (tympanostomy tubes): Class II recall for three lots that did not undergo required sterilization. Stop use and return affected unused product.

FDA posted the records November 6; Medtronic initiated the recall September 24. Affected products are Sheehy 5PK BUTTON REF 1013301, lots 0231048279 and 0231048280, and BOBBIN 5PK REF 1010201, lot 0231048277. The missed sterilization process can lead to infection and inflammation after implantation.

Stop use, segregate and quarantine affected unused product, then return it to Medtronic. Complete the customer confirmation form. Patients with affected implants should continue to be monitored under standard clinical practice. The FDA records do not call for preventive removal solely because of this notice.

FDA Sheehy BUTTON record · FDA BOBBIN record

restor3d Veritas shoulder liners: Class II recall because a liner may not stay securely in place, potentially causing dislocation or revision surgery. Do not implant or use affected units.

FDA posted the record November 3; restor3d initiated the action October 1. It covers all lots of size 1–2, 40 mm polymer liners 3500-140C3, 3500-140U3, 3500-140C1 and 3500-140U1. Pairing the smaller stems with a 40 mm glenosphere can create excessive loading and insufficient liner retention.

Do not implant or otherwise use the affected units. The October 7 notice requested the field-action response form within 10 business days. Promptly report relevant complications to restor3d. The FDA record does not recommend routine revision, removal or special follow-up solely because of this action.

FDA affected products and instructions

AVID Halyard MINOR PACK surgical kits: Class II recall for a potentially compromised seal. Do not use the affected kit; discard or return it.

FDA posted the record November 3; AVID initiated the action September 8. Model VASF105-08, lot 1659384, may have an open header-bag seal that compromises sterility. This record is separate from the AVID IV Start Kit recall.

AVID's October 6 update directs customers not to use affected kits and to discard or return them. Contact customer service for a return authorization if returning a kit, and complete the response form. The update replaces the earlier instruction to inspect the seal.

FDA model, lot and updated instructions

Nova StatStrip Gen 2.0: Models 63685/66739 on all firmware remain subject to the FDA correction instructions; the prior scope and actions remain in the November 2 issue. A software fix and recall closure have not been confirmed.

Sources and scope

This issue covers November 2–8, 2026. Earlier incidents and notices are identified by date in the stories. Sources include FDA notices, vendor advisories, government publications and CISA's KEV catalog, version 2026.11.06 when checked. The French blood-service details are attributed to The Record, and University Hospitals' November 7 MyChart update is attributed to Cleveland 19. Selected sources were checked November 9 UTC. Coverage is selective, and the FDA tracker is not a database-wide recall search.